Corient Private Wealth LP increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 485.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,525 shares of the biotechnology company's stock after buying an additional 29,452 shares during the period. Corient Private Wealth LP's holdings in BioMarin Pharmaceutical were worth $2,033,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of BMRN. Primecap Management Co. CA bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth $811,962,000. Norges Bank acquired a new stake in BioMarin Pharmaceutical in the fourth quarter valued at $447,572,000. Caisse de depot et placement du Quebec bought a new position in shares of BioMarin Pharmaceutical during the second quarter worth about $70,749,000. Bank of New York Mellon Corp bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth approximately $66,107,000. Finally, River Road Asset Management LLC acquired a new position in BioMarin Pharmaceutical in the fourth quarter valued at $53,865,000. Institutional investors own 98.71% of the company's stock.
BioMarin Pharmaceutical Price Performance
Shares of NASDAQ:BMRN opened at $62.21 on Thursday. The company's fifty day moving average price is $64.09 and its 200-day moving average price is $58.66. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a market capitalization of $12.04 billion, a price-to-earnings ratio of 168.14, a PEG ratio of 0.45 and a beta of 0.24.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business's revenue was up 20.0% compared to the same quarter last year. During the same period last year, the firm posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on BMRN. Weiss Ratings cut shares of BioMarin Pharmaceutical from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, September 18th. Citigroup lifted their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Canaccord Genuity Group raised their price objective on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Morgan Stanley upped their price target on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Oppenheimer raised their price objective on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $89.17.
Check Out Our Latest Stock Report on BMRN
BioMarin Pharmaceutical Company Profile
(
Free Report)
BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.
BioMarin's marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
